FIGURE 4.
The predicted risk of grade ≥3 xerostomia at 9, 12, and 24 months after radiotherapy, using the Dtot dose variable. ∗Note that not all categories are significantly different from each other with respect to the endpoint – the p-value only refers to the difference from the reference category (see Table 2 for p-values). “No” was reference for concomitant chemotherapy and Erbitux was not significantly different.